Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients
Ruaño G, Goethe J, Caley C, Woolley S, Holford T, Kocherla M, Windemuth A, Leon J. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Molecular Psychiatry 2007, 12: 474-482. PMID: 17199131, DOI: 10.1038/sj.mp.4001944.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnalysis of VarianceAntipsychotic AgentsApolipoproteinsAppetite RegulationAryldialkylphosphataseBenzodiazepinesCross-Sectional StudiesFemaleGenomicsHumansLipid MetabolismMaleMental DisordersMiddle AgedOlanzapinePolymorphism, Single NucleotideReceptors, Cell SurfaceReceptors, LeptinReceptors, Neuropeptide YRisperidoneScavenger Receptors, Class BWeight GainConceptsSingle nucleotide polymorphismsPhysiogenomic analysisNeuropeptide Y receptor Y5Receptor single nucleotide polymorphismsScavenger receptor class BRisperidone-treated patientsSide effect profileReceptor class BDrug-specific mechanismsSimilar side effectsGenetic associationAtypical antipsychoticsEffect profileAppetite peptidesApolipoprotein ELeptin receptorParaoxonase 1Side effectsPatientsOlanzapineRisperidoneElevated weightApolipoprotein A4Lipid homeostasisMember 1